U.S. FDA Advisory Committee Votes Nine to One in Favor of Remestemcel-L (Ryoncil™) for Efficacy in Children With Steroid-Refractory Acute Graft Versus Host DiseaseGlobeNewsWire • 08/14/20
FDA Advisory Committee Sets Review Date for Mesoblast’s remestemcel-L in Pediatric Steroid-Refractory Acute Graft Versus Host DiseaseGlobeNewsWire • 07/21/20
Mesoblast Solving Unmet Medical Needs Including Severe ARDS Caused By COVID-19Seeking Alpha • 07/17/20
Expanded Access Protocol Initiated for Compassionate Use of Remestemcel-L in Children With Multisystem Inflammatory Syndrome Associated With COVID-19GlobeNewsWire • 07/06/20
Remestemcel-L Improves Respiratory and Functional Outcomes in Patients With Inflammatory Lung DiseaseGlobeNewsWire • 06/01/20
Mesoblast Ltd. (MESO) CEO Silviu Itescu on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/29/20
Mesoblast Reports Strong Financial Position and Substantial Operational Progress For the Period Ended March 31, 2020GlobeNewsWire • 05/27/20
Clinical Outcomes Using RYONCIL™ (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host Disease Published in Three Articles in Biology of Blood and Marrow TransplantationGlobeNewsWire • 05/25/20
Mesoblast Successfully Completes Financing to Scale-Up Manufacturing of Remestemcel-L for COVID-19 ARDSGlobeNewsWire • 05/13/20
First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress SyndromeGlobeNewsWire • 05/06/20
Phase 2/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins EnrollmentGlobeNewsWire • 04/30/20